Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 8 min ago
Peer-reviewedLicence not statedNeuro-Oncology

cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas

  • Daniel Jay Brat1
  • Kenneth Aldape2
  • Pim J. French3
  • David N. Louis4
  • MacLean P. Nasrallah5
  • Guido Reifenberger6
  • David Reuß7
  • Mehdi Touat8
  • Martin J. van den Bent3
  • Pieter Wesseling9,10
  • Dominique F. Figarella-Branger11
11 affiliations
  1. 1Department of Pathology, Northwestern University Feinberg School of Medicine , Chicago, Illinois,
  2. 2Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, Minnesota,
  3. 3Brain Tumor Center, Department of Neurology, Erasmus MC Cancer Institute, University Medical Center , Rotterdam,
  4. 4Department of Pathology, Mass General Brigham, Harvard Medical School , Boston, Massachusetts,
  5. 5Department of Pathology, Perelman School of Medicine at the University of Pennsylvania , Philadelphia, Pennsylvania,
  6. 6Institute of Neuropathology, Heinrich Heine University Medical Faculty and University Hospital Düsseldorf , Düsseldorf,
  7. 7Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, University of Heidelberg , Heidelberg,
  8. 8Department of Neuro-oncology, Sorbonne University, Inserm, CNRS, UMRS 1127, Paris Brain Institute (PBI), AP-HP Sorbonne University, La Pitié Salpêtrière - Charles Foix Hospital Group , Paris,
  9. 9Department of Pathology, Amsterdam University Medical Centers , Amsterdam,
  10. 10Princess Máxima Center for Pediatric Oncology , Utrecht,
  11. 11Aix-Marseille Univ, APHM, CNRS, INP, Institut de Neurophysiopathologie, GlioME Team, CHU Timone, Service d’Anatomie Pathologique et de Neuropathologie , Marseille,
Open at sourceDOICite

Related

  1. Refining Risk Stratification in Light-Chain Cardiac Amyloidosis: A Single-Center Ambispective Cohort Study
    Emre Ozerdem, Menekse Gerede Uludag, Seyhmus Atan +6
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Gliomas grading prediction using multicenter 3T Magnetic Resonance Spectroscopy
    Di Guo, Kaiwei Xie, Jiacheng Lin +7
    BMC Medical ImagingPeer-reviewedCC BY 4.0Full textMedical imaging & radiologyPMC
  3. 5.0T multi-parametric diffusion MRI histogram analysis for prostate cancer pathology grading and adverse pathological factors
    Sen Xing, Ying Tan, Xinghua Liu +7
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  4. Reclassifying renal cell carcinoma with pathologic lymph node metastasis: An approach to refining prognostic stratification in patients with AJCC III and IV stages
    Xu Bai, Tongyu Jia, Houming Zhao +16
    Chinese Medical JournalPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineDOAJPMC
  5. Hybrid grading systems improve progression risk stratification in non‐invasive papillary urothelial carcinoma and support a histomorphological continuum of disease progression
    Jane K Nguyen, Marcello P Toscano, Jianbo Li +14
    HistopathologyPeer-reviewedCC BY 4.0Full text1 citedSurgery & anaesthesiaPMC

Cite

BibTeXRIS
BibTeX
@article{brat2026cimpactnow,
  title = {{cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas}},
  author = {Daniel Jay Brat and Kenneth Aldape and Pim J. French and David N. Louis and MacLean P. Nasrallah and Guido Reifenberger and David Reuß and Mehdi Touat and Martin J. van den Bent and Pieter Wesseling and Dominique F. Figarella-Branger},
  journal = {Neuro-Oncology},
  year = {2026},
  month = may,
  doi = {10.1093/neuonc/noag108},
  url = {https://pubmed.ncbi.nlm.nih.gov/42152226/},
}
RIS
TY  - JOUR
TI  - cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas
AU  - Daniel Jay Brat
AU  - Kenneth Aldape
AU  - Pim J. French
AU  - David N. Louis
AU  - MacLean P. Nasrallah
AU  - Guido Reifenberger
AU  - David Reuß
AU  - Mehdi Touat
AU  - Martin J. van den Bent
AU  - Pieter Wesseling
AU  - Dominique F. Figarella-Branger
PY  - 2026
DA  - 2026/05/14
JO  - Neuro-Oncology
DO  - 10.1093/neuonc/noag108
UR  - https://pubmed.ncbi.nlm.nih.gov/42152226/
SN  - 1522-8517
SN  - 1523-5866
ER  -